All In Biotech

Drug Trial Radar · NCT02872701

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

A Phase 2, Single Dose, Open-Label, Exploratory Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

Last checked: Nov 19, 2026Latest source record: Mar 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

100

Actual

Start

May 4, 2017

Primary completion

Oct 31, 2018

Study completion Nov 30, 2018

Sponsor

Lead sponsor
On Target Laboratories, LLCIndustry
Sponsor type
Industry
Collaborators
Medelis Inc.
First posted
Aug 19, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/positron emission tomography imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to assess the safety and tolerability of single intravenous doses of OTL38.

Conditions

  • Lung Neoplasms
  • Lung Cancer

Interventions

  • OTL38 for InjectionDrug

    Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL

  • Near infrared camera imaging systemDevice

    Near infrared camera imaging system

  • Endoscopic or Thoracic SurgeryProcedure

    Endoscopic or Thoracic Surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity or True Positive Rate (TPR)Time frame: 1 day
  2. False Positive Rate (FPR)Time frame: 1 day

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • Leiden University Medical Center

    Leiden, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.